X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pde2a (14) 14
index medicus (11) 11
animals (10) 10
cyclic nucleotide phosphodiesterases, type 2 - metabolism (9) 9
cyclic nucleotide phosphodiesterases, type 2 - antagonists & inhibitors (7) 7
humans (7) 7
rats (7) 7
cgmp (6) 6
brain (5) 5
cyclic gmp - metabolism (5) 5
cyclic-nucleotide phosphodiesterases (5) 5
male (5) 5
pharmacology & pharmacy (5) 5
phosphodiesterase inhibitors - pharmacology (5) 5
schizophrenia (5) 5
cognition (4) 4
memory (4) 4
neurosciences (4) 4
pde10a (4) 4
rat-brain (4) 4
rats, sprague-dawley (4) 4
autoradiography (3) 3
brain - metabolism (3) 3
chemistry, medicinal (3) 3
chemistry, multidisciplinary (3) 3
drug design (3) 3
expression (3) 3
hippocampus (3) 3
mice (3) 3
organic chemistry (3) 3
pde2a inhibitors (3) 3
phosphodiesterase (3) 3
phosphodiesterase 2a (3) 3
phosphodiesterase inhibitors - chemistry (3) 3
pyrazoles - pharmacology (3) 3
pyrimidines - pharmacology (3) 3
administration, oral (2) 2
alzheimer's disease (2) 2
antipsychotic-drugs (2) 2
avoidance learning - drug effects (2) 2
biochemistry & molecular biology (2) 2
brain - enzymology (2) 2
camp (2) 2
cgmp-stimulated phosphodiesterase (2) 2
cognition - drug effects (2) 2
cognition disorders - drug therapy (2) 2
cognition disorders - metabolism (2) 2
cyclic amp - metabolism (2) 2
dose-response relationship, drug (2) 2
drug discovery (2) 2
efficacy (2) 2
identification (2) 2
inhibitors (2) 2
mice, inbred icr (2) 2
micellar hplc (2) 2
object memory (2) 2
pde9a (2) 2
pet imaging in brain (2) 2
phosphodiesterase inhibitors - metabolism (2) 2
phosphodiesterase inhibitors - pharmacokinetics (2) 2
positron emission (2) 2
positron emission tomography (2) 2
potent (2) 2
pyrazines - chemistry (2) 2
pyrazines - pharmacology (2) 2
pyrazoles - chemistry (2) 2
pyrazoles - pharmacokinetics (2) 2
pyrimidines - chemistry (2) 2
quinoxalines - pharmacology (2) 2
rats, wistar (2) 2
recognition - drug effects (2) 2
specificity (2) 2
stimulated phosphodiesterase (2) 2
structure-based design (2) 2
synaptic plasticity (2) 2
tomography (2) 2
type-2 (2) 2
10a inhibitors (1) 1
3',5'-cyclic-gmp phosphodiesterases - genetics (1) 1
3',5'-cyclic-gmp phosphodiesterases - metabolism (1) 1
3',5'-cyclic-nucleotide phosphodiesterase (1) 1
3t3 cells (1) 1
5'-splice variants (1) 1
5′-splice variants (1) 1
activation (1) 1
adenosine - pharmacology (1) 1
adenylyl-cyclase (1) 1
aging (1) 1
alzheimers-disease (1) 1
alzheimer’s disease (1) 1
amino acid sequence (1) 1
ampa (1) 1
analysis (1) 1
animal-models (1) 1
anp receptor (1) 1
antipsychotic (1) 1
antipsychotic agents - metabolism (1) 1
antipsychotic agents - pharmacology (1) 1
antipsychotic agents - toxicity (1) 1
antipsychotics (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


MOLECULES, ISSN 1420-3049, 08/2019, Volume 24, Issue 15, p. 2791
Phosphodiesterase 2A (PDE2A) is highly expressed in distinct areas of the brain, which are known to be related to neuropsychiatric diseases. The development of... 
Phosphodiesterase 2A (PDE2A) | BIOCHEMISTRY & MOLECULAR BIOLOGY | Positron Emission Tomography (PET) | PDE2A INHIBITORS | Benzoimidazotriazine (BIT) | OXETANES | CHEMISTRY, MULTIDISCIPLINARY | POTENT | Mouse Liver Microsomes (MLM) | BIOCHEMISTRY | BRAIN-PENETRANT | TARGETS | fluorinated | STRUCTURE-BASED DESIGN
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 09/2017, Volume 60, Issue 18, pp. 7677 - 7702
Journal Article
Behavioural Brain Research, ISSN 0166-4328, 12/2019, Volume 376, p. 112192
Changes in the cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) signaling are implicated in older people with dementia. Drugs... 
Aging | TAK-915 | Cognition | PDE2A
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 08/2015, Volume 761, pp. 79 - 85
Journal Article
Journal Article
Chemical and Pharmaceutical Bulletin, ISSN 0009-2363, 2017, Volume 65, Issue 11, pp. 1058 - 1077
It has been hypothesized that selective inhibition of phosphodiesterase (PDE) 2A could potentially be a novel approach to treat cognitive impairment in... 
pyrazolo[1,5-a]pyrimidine | structure-based drug design | schizophrenia | phototoxicity | intramolecular hydrogen bond | phospodiesterase 2A | Phototoxicity | Pyrazolo[1,5-a]pyrimidine | Schizophrenia | Phospodiesterase 2A | Structure-based drug design | Intramolecular hydrogen bond | CHEMISTRY, MEDICINAL | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | NEGATIVE SYMPTOMS | PDE2A INHIBITORS | DIFFRACTION DATA | SYNAPTIC PLASTICITY | CHEMISTRY, MULTIDISCIPLINARY | ANTIPSYCHOTIC-DRUGS | ANIMAL-MODELS | CGMP | PHARMACOLOGY & PHARMACY | RAT-BRAIN | Cyclic Nucleotide Phosphodiesterases, Type 2 - antagonists & inhibitors | Pyridines - chemistry | Humans | Rats, Long-Evans | Cercopithecus aethiops | Cognition Disorders - metabolism | Male | Structure-Activity Relationship | Pyrimidines - chemistry | Dose-Response Relationship, Drug | Thermodynamics | Pyrazoles - chemistry | Molecular Structure | Phosphodiesterase Inhibitors - chemistry | Pyrazoles - pharmacology | Cell Survival - drug effects | Administration, Oral | Cyclic Nucleotide Phosphodiesterases, Type 2 - metabolism | Solubility | Phosphodiesterase Inhibitors - pharmacology | Rats | Pyrimidines - pharmacology | Cognition Disorders - drug therapy | Drug Discovery | Mice, Inbred ICR | Phosphodiesterase Inhibitors - administration & dosage | Pyrazines - chemistry | Animals | Mice | Mice, Inbred BALB C | Pyridines - pharmacology | Powder Diffraction | Pyrazines - pharmacology | COS Cells | 3T3 Cells
Journal Article
Journal Article
Journal Article
MOLECULES, ISSN 1420-3049, 06/2015, Volume 20, Issue 6, pp. 9591 - 9615
Phosphodiesterase 2A (PDE2A) is highly and specifically expressed in particular brain regions that are affected by neurological disorders and in certain... 
SELECTIVE-INHIBITION | PDE2 | RAT | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | PDE2A | micellar HPLC | CHEMISTRY, ORGANIC | OBJECT MEMORY | PET LIGANDS | PET imaging in brain | HIPPOCAMPUS | CGMP | TUMOR-GROWTH INHIBITION | Alzheimer's disease | TYPE-2
Journal Article
Journal Article
05/2014, ISBN 9780470566688, 38
The pharmacological targeting of different phosphodiesterase (PDE) isoforms is predicted to have diverse, isoform‐specific effects on central nervous system... 
PDE5A | PDE10A | PDE4 | PDE9A | PDE2A | central nervous system | Central nervous system
Book Chapter
European Journal of Biochemistry, ISSN 0014-2956, 01/2001, Volume 268, Issue 1, pp. 168 - 178
PDE11A is a dual‐substrate, cAMP and cGMP, cyclic nucleotide phosphodiesterase (PDE). Presently four unique variants carrying distinct GAF sequences in the... 
genome | PDE11A | GAF domain | PDE2A | phosphodiesterase
Journal Article